JPRN-jRCT2080222723
Completed
Phase 2
Phase IIa Study of F-1311 in Patients with Prostate Cancer
ConditionsProstate cancer
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Prostate cancer
- Sponsor
- PDRadiopharma Inc.
- Enrollment
- 15
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Biopsy confirmed presence of adenocarcinoma of the prostate gland.
- •\-Gleason score \>\= 7
- •\-PSA \> 20 ng/m
Exclusion Criteria
- •\-Subjects have received or have been receiving treatment or medication for prostate cancer.
- •\-Subjects have severe hepatic or renal dysfunction.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Phase IIb Study of F-1311 in Patients with Prostate CancerProstate CancerJPRN-jRCT2080223135PDRadiopharma Inc.56
Active, not recruiting
Not Applicable
A Clinical Phase II Study in Patients with Prostate Cancer and Bone Metastases with KML001 (KOMINOX®) - KML001 in patients with prostate cancer and bone metastasesProstate Cancer MetastaticMedDRA version: 8.1Level: LLTClassification code 10036909Term: Prostate cancer metastaticEUCTR2006-005607-33-DEKOMINOX USA, Inc.
Active, not recruiting
Phase 1
A Phase 1/2, Open-Label Study in Men with Prostate Cancer to Assess the Safety, Pharmacokinetics, and Testosterone-Lowering Efficacy of TAK-448, Administered as a 1 Month Depot, Including a Randomized Portion With a Group Administered LeuproreliProstate cancerMedDRA version: 12.1Level: LLTClassification code 10007113Term: Cancer of prostateEUCTR2009-017668-18-FRMillennium Pharmaceuticals, Inc.
Active, not recruiting
Not Applicable
Testing of a new drug in men with prostate cancer that may help lower testosterone levels.EUCTR2009-017668-18-BEMillennium Pharmaceuticals, Inc.123
Completed
Phase 2
Pilot study: Fosfomycin levels in prostate tissue after oral and iv administratioprostatitisprostate infection10004018NL-OMON44736HagaZiekenhuis30